Key facts
- It has raised $42.6M; the latest was Early Stage VC ($27.9M) in Sep 2025.
- Notable investors include Highlight Capital, Fuzhe Capital, HFI Investment Group, Taikun Fund, Hangzhou Linzhuo Industry Investment — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for E-nitiateBio
- ·The full record, as it builds
Funding rounds
No funding rounds for E-nitiateBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About E-nitiateBio
Developer of new drugs designed for autoimmune diseases. The company focuses on researching and developing innovative medicines for dermatology and autoimmune diseases, improving the quality of human life and solving the unmet needs of patients.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- enitiatebio.com/
- Ownership
- Privately Held (backing)
E-nitiateBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in E-nitiateBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on E-nitiateBio in its N-PORT filings yet. We sweep new filings monthly.